Search Results - "Gottesman, M H"

A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium by Jacobs, L D, Wende, K E, Brownscheidle, C M, Apatoff, B, Coyle, P K, Goodman, A, Gottesman, M H, Granger, C V, Greenberg, S J, Herbert, J, Krupp, L, Lava, N S, Mihai, C, Miller, A E, Perel, A, Smith, C R, Snyder, D H

“…We have obtained a current profile of multiple sclerosis (MS) in New York State through a centralized patient registry and standardized data collection…”
Get full text

Neutralizing antibodies to 500 μg interferon beta-1b: 28-month results of the IDEAS extension trial by Gottesman, MH, Friedman-Urevich, S., Boylan, E., Cheng, D.

“…The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had…”
Get full text

Interferon beta-1b (Betaseron®/Betaferon®) is well tolerated at a dose of 500 μg : interferon dose escalation assessment of safety (IDEAS) by GOTTESMAN, M. H, FRIEDMAN-UREVICH, S

Get full text

Modified Brown-Séquard syndrome following coronary artery bypass graft : case report by GOTTESMAN, M. H, SARAYA, I, TENTI, F

“…A 75 year old man underwent a triple coronary artery bypass graft performed with intra-aortic balloon pump assistance. Left leg weakness developed on the first…”
Get full text

Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium by WEINSTOCK-GUTTMAN, B, JACOBS, L. D, GOTTESMAN, M. H, HERBERT, J, HOLUB, R, LAVA, N. S, LENIHAN, M, LUSINS, J, MIHAI, C, MILLER, A. E, PEREL, A. B, SNYDER, D. H, BROWNSCHEIDLE, C. M, BAKSHI, R, GRANGER, C. V, GREENBERG, S. J, JUBELT, B, KRUPP, L, MUNSCHAUER, F. E, RUBIN, D, SCHWID, S, SMIROLDO, J, BAIER, M, REA, D. F, APATOFF, B. R, BLITZ, K. M, COYLE, P. K, FRONTERA, A. T, GOODMAN, A. D

“…The objective of this study was to determine the clinical characteristics of multiple sclerosis (MS) in African American (AA) patients in the New York State…”
Get full text

The CVC removal distress syndrome: an unappreciated complication of central venous catheter removal by Kim, D K, Gottesman, M H, Forero, A, Han, D, Myers, D W, Forlenza, R, Golzarian, J

“…The removal of a central venous catheter (CVC) can be complicated by rare but potentially life-threatening neurocardiopulmonary distress. The clinical courses…”
Get more information

Cardiac arrest caused by trigeminal neuralgia by Gottesman, M H, Ibrahim, B, Elfenbein, A S, Mechanic, A, Hertz, S

“…A 67-year-old man with a 12-year history of trigeminal neuralgia experienced multiple fainting episodes preceded by right facial pain. One episode resulted in…”
Get more information

Spinal subdural empyema: appearance on intraoperative sonography by Price, D B, Gottesman, M H, Adelman, R, Schneider, S J

Get more information

Multiple sclerosis characteristics in A frican A merican patients in the New York State Multiple Sclerosis C onsortium by Weinstock-Guttman, B, Jacobs, L D, Brownscheidle, C M, Baier, M, Rea, D F, Apatoff, B R, Blitz, K M, Coyle, P K, Frontera, A T, Goodman, A D, Gottesman, M H, Herbert, J, Holub, R, Lava, N S, Lenihan, M, Lusins, J, Mihai, C, Miller, A E, Perel, A B, Snyder, D H, Bakshi, R, Granger, C V, Greenberg, S J, Jubelt, B, Krupp, L, Munschauer, F E, Rubin, D, Schwid, S, Smiroldo, J

“…The objective of this study was to determine the clinical characteristics of multiple sclerosis (MS) in A frican A merican (A A) patients in the New York State…”
Get full text

Longitudinal correlates of fatigue in multiple sclerosis by Patrick, E, Christodoulou, C, Krupp, LB

“…Objective To determine the predictors of longitudinal changes in fatigue based on pain, mood, and neurological impairment across multiple sclerosis (MS)…”
Get full text

Neutralizing antibodies to 500 kg interferon beta-1b: 28-month results of the IDEAS extension trial by Gottesman, M H, Friedman-Urevich, S, Boylan, E, Cheng, D

“…The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had…”
Get full text

Interferon beta-1b (Betaseron®/Betaferon®) is well tolerated at a dose of 500 mg: interferon dose escalation assessment of safety (IDEAS) by Gottesman, M H, Friedman-Urevich, S

“…The approved interferon beta-1b (Betaseron®/Betaferon®) dose is 250 mg (8 MIU) administered subcutaneously (sc) every other day (eod). Clinical trial data…”
Get full text

Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS) by Gottesman, M H, Friedman-Urevich, S

“…The approved interferon beta-1b (Betaseron/Betaferon) dose is 250 microg (8 MIU) administered subcutaneously (sc) every other day (eod). Clinical trial data…”
Get full text

Neutralizing antibodies to 500 microg interferon beta-1b: 28-month results of the IDEAS extension trial by Gottesman, M H, Friedman-Urevich, S, Boylan, E, Cheng, D

“…The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had…”
Get full text

Interferon beta-1b (Betaseron®/Betaferon®) is well tolerated at a dose of 500 [phi]g: interferon dose escalation assessment of safety (IDEAS) by Gottesman, M H, Friedman-Urevich, S

“…The approved interferon beta-1b (Betaseron/Betaferon) dose is 250 microg (8 MIU) administered subcutaneously (sc) every other day (eod). Clinical trial data…”
Get full text

Neutralizing antibodies to 500 [mu]g interferon beta-1b: 28-month results of the IDEAS extension trial by Gottesman, MH, Friedman-Urevich, S, Boylan, E, Cheng, D

“…The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had…”
Get full text

A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium by Jacobs, L.D., Wende, K.E., Brownscheidle, C.M., Apatoff, B., Coyle, P.K., Goodman, A., Gottesman, M.H., Granger, C.V., Greenberg, S.J., Herbert, J., Krupp, L., Lava, N.S., Mihai, C., Miller, A.E., Perel, A., Smith, C.R., Snyder, D.H.

“…We have obtained a current profile of multiple sclerosis York State through a centralized patient registry and standardized data collection instrument…”
Get full text

Tissue plasminogen activator for acute stroke in everyday clinical practice by Wirkowski, Elzbieta J., Gottesman, Malcolm H., Mazer, Cynthia, Brody, Gerald M., Manzella, Stephanie M.

“…Thrombolysis for acute ischemic stroke has become a reality. The aim of our study was to assess the opportunity and practicality of establishing acute stroke…”
Get full text

DRAINING THE DISMAL SWAMP: THE CASE FOR FEDERAL CHOICE OF LAW STATUTES by Gottesman, Michael H

Get full text